Peritumoral MRE Stiffness for Predicting Resection Margin Status and Recurrence in Liver Cancer
Starting soon
Conditions studied: Hepato Cellular Carcinoma, Intrahepatic Bile Duct Carcinoma, Metastatic Hepatocellular Carcinoma
In brief
Microscopic residual tumor at the resection margin is a critical risk factor for recurrence in patients undergoing hepatectomy for liver cancer, yet current detection relies solely on postoperative pathological examination of the resected specimen, which reflects only the removed tissue rather than the actual remnant liver in the patient. How to non-invasively detect residual tumor at the resection margin of the remnant liver after surgery remains an important unresolved problem in the surgical management of liver cancer. We hypothesize that tissue stiffness at the resection margin of the remnant liver, measured by postoperative three-dimensional magnetic resonance elastography (3D-MRE), may reflect microscopic residual tumor and may therefore correlate with pathological resection margin status and be predictive of postoperative tumor recurrence. This study aims to prospectively evaluate the diagnostic performance of postoperative 3D-MRE in detecting residual tumor at the resection margin, using pathological resection margin status as the reference standard, and to further assess its value in predicting tumor recurrence in patients undergoing hepatectomy for liver cancer.
Key facts
- Study ID
- NCT07704216
- Run by
- Second Affiliated Hospital of Xi'an Jiaotong University
- People needed
- 150
- Starts
- 2026-08-01
- Expected to finish
- 2031-10-01
- Last updated by the study team
- 2026-07-15
Who can join
Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age 18-80 years
- Pathologically confirmed diagnosis of hepatocellular carcinoma, intrahepatic cholangiocarcinoma, or liver metastasis (e.g., from colorectal cancer)
- Underwent curative-intent hepatectomy with available postoperative pathological resection margin assessment
- Child-Pugh class A or B liver function (for patients with primary liver cancer)
- Able to undergo 3D-MRE examination at postoperative day 7-14
- Provision of signed and dated informed consent
You may not qualify if…
- Contraindication to MRI (e.g., non-MRI-compatible implants, severe claustrophobia)
- Palliative or non-curative surgery (R2 resection)
- Presence of unresectable extrahepatic disease at the time of surgery
- Reoperation or unplanned return to surgery within 14 days after the initial hepatectomy
- Severe postoperative complications precluding MRI examination at postoperative day 7-14 (e.g., unstable vital signs, need for intensive care)
- Death within 14 days after surgery from non-tumor-related causes
- Prior history of liver resection or liver transplantation
- Pregnant or breastfeeding women
- Anticipated poor compliance with postoperative MRE examination or follow-up
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.